Sydney:12/24 22:26:56

Tokyo:12/24 22:26:56

Hong Kong:12/24 22:26:56

Singapore:12/24 22:26:56

Dubai:12/24 22:26:56

London:12/24 22:26:56

New York:12/24 22:26:56

Live Updates  >  Live Update Details

2025-08-01 15:46:26

Borri Pharmaceuticals and China Resources Sanjiu Reach Collaboration on Innovative GLP-1/GIP Dual-Target Drug: (1) Borri Pharmaceuticals announced on August 1st that it had signed an agreement with China Resources Sanjiu, granting it exclusive rights in mainland China for the development, production, and commercialization of its independently developed BGM0504 injection (an innovative GLP-1/GIP dual-target drug). (2) The drug, which has potential therapeutic effects such as lowering blood sugar, reducing weight, and treating non-alcoholic steatohepatitis, is not currently available domestically or internationally.

Real-Time Popular Commodities

Instrument Current Price Change

XAU

3363.16

73.24

(2.23%)

XAG

37.003

0.319

(0.87%)

CONC

67.26

-2.00

(-2.89%)

OILC

69.48

-2.30

(-3.20%)

USD

98.678

-1.389

(-1.39%)

EURUSD

1.1594

0.0001

(0.01%)

GBPUSD

1.3282

-0.0001

(-0.00%)

USDCNH

7.1909

-0.0006

(-0.01%)

Hot News